This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Emergent BioSolutions Inc (EBS)

NYSE: Health Care

Company Income Statement
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Sales 312.74M 281.89M 273.38M 286.17M
Cost of Sales 43.17M 34.88M 32.82M 41.12M
Gross Operating Profit 269.58M 247.01M 240.57M 245.05M
Selling, General, and Administrative Expenses 87.88M 76.02M 74.28M 76.20M
Research & Development 119.93M 120.23M 124.83M 89.30M
Operating Income before D & A (EBITDA) 61.76M 50.76M 41.45M 79.55M
Depreciation & Amortization 18.96M 11.20M 9.36M 5.99M
Interest Income 139.00K 134.00K 105.00K 832.00K
Other Income - Net 426.00K 1.97M -261.00K -1.02M
Special Income / Charges 0.00 -9.60M 0.00 0.00
Total Income Before Interest Expenses (EBIT) 43.37M 32.07M 31.94M 73.37M
Interest Expense 0.00 6.00K 0.00 0.00
Pre-Tax Income 43.37M 32.06M 31.94M 73.37M
Income Taxes 13.11M 13.92M 15.83M 26.18M
Minority Interest -876.00K -5.38M -6.91M -4.51M
Net Income From Continuing Operations 30.26M 18.14M 16.11M 47.18M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 30.26M 18.14M 16.11M 47.18M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 31.14M 23.52M 23.02M 51.70M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
30.26M 27.74M 16.11M 47.18M
Preferred Dividends
Net Income Available To Common 30.26M 18.14M 16.11M 47.18M
Basic EPS from Continuing Ops. 0.86 0.65 0.65 1.63
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 0.86 0.65 0.65 1.63
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 0.86 0.65 0.65 1.63
Basic Normalized Net Income/Share 0.86 1.00 0.65 1.63
EPS fr Continuing Ops. 0.85 0.65 0.64 1.59
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 0.85 0.65 0.64 1.59
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 0.85 0.65 0.64 1.59
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.85 0.99 0.64 1.59
Dividends Paid per Share 0.00 0.00 0.00 0.00
EBS News

EBS Emergent BioSolutions Inc

Analysts Ratings for EBS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 1 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET EBS ANALYST REPORT

Brokerage Partners

EBS Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs